Events
GENFIT announced the results of the voting by shareholders at the Ordinary Shareholders’ Meeting which took place on June 13, 2019, in Lille, France.
Clinical Ink is pleased to announce that Jonathan Andrus, chief business officer at Clinical Ink, has been invited to be a panelist in a public meeting hosted by the Duke-Margolis Center for Health Policy on July 17, 2019, in Washington, D.C. The workshop, convened under a cooperative agreement with the FDA, will discuss opportunities to improve the implementation of risk-based monitoring (RBM) in clinical investigations.
The International Biofilm Summit, addressing the main threat to food contamination, seizes the opportunity of its third edition on 23-24 October to take it to the next level.
As a sign of its international importance, the BIO Asia-Taiwan 2019 exhibition will feature 18 national pavilions, while the conference will feature speakers from 25 countries
Cipher Pharmaceuticals Inc., in accordance with Toronto Stock Exchange requirements, announced the voting results for the election of directors at its Annual and Special Meeting of Shareholders held on June 11, 2019 in Toronto, Ontario.
Neos Therapeutics, Inc. announced that Jerry McLaughlin, its Chief Executive Officer, will present a company overview at two upcoming conferences in June.
Pyrrolobenzodiazepine-based antibody drug conjugates demonstrate potential for the treatment of relapsed or refractory lymphomas as single agents and in combination therapies
TLC599 showed locally sustained release profile up to 120 days, dose proportionality, minimal systemic exposure and potential for repeat dosing
A year ago, GENFIT gathered an international coalition to support The NASH Education Program and launch the 1st successful edition of International NASH Day
Heidelberg Pharma AG announced that they will present their proprietary technology for Antibody Targeted Amanitin Conjugates as potential therapeutic modality for cancer therapy at two upcoming scientific conferences.
PRESS RELEASES